Successful treatment of major oral aphthous ulcers in HIV-1 infection after highly active antiretroviral therapy  by Alegre, M. et al.
LI
1nternational Journal of Infectious Diseases (2007) 11, 278—285
http://intl.elsevierhealth.com/journals/ijidETTERS TO THE EDITORSuccessful treatment of major oral aphthous
ulcers in HIV-1 infection after highly active
antiretroviral therapy
Oral recurrent aphthous ulcers are a well-recognized com-
plication in HIV-1-infected patients. Multiple pathogenic
mechanisms for this disorder have been proposed, but the
exact cause remains unknown. Severity of lesions usually
correlates with the stage of immunosuppression and response
to available treatments is often unsatisfactory. We describe
herein a patient with multiple oral major aphthous ulcers
who failed to respond to conventional treatments, and only
improved after initiation of highly active antiretroviral ther-
apy (HAART).
The patient was a 34 year-old Caucasian HIV-1-infected
man who had been diagnosed in 2001. He had been referred
with the appearance of recurrent minor oral aphthous ulcers
several years previously. He had not had opportunistic infec-
tions and he was antiretroviral naı¨ve. In March 2003, he
presented with a painful ulceration of 2.1  1.5-cm diameter
in the anterior tonsillar plate and palate. Systemic metroni-
dazole and valaciclovir were started empirically without
improvement. Bacteriologic, virologic, andmycologic cultures
were negative and histopathology demonstrated a non-
specific deep ulcer with acute and chronic inflammation.
The diagnosis of major aphthous disease was entertained,
and treatment with oral colchicine, topical corticosteroid
gel, and viscose lidocaine solution was started, which was
followed by a complete resolution of the ulcer after two
months. Laboratory parameters including iron, vitamin B12,
folic acid, zinc, and antistreptolysin antibodies were all
normal. Serologic evidence for syphilis was negative.
Five months later, ulcers recurred and were larger and
more painful. They were localized under the tongue, com-
pressing the anterior tonsillar plate and the palate, and on
the labial mucosa (Figure 1). Treatment was restarted with-
out improvement. Treatment with topical 0.2% tacrolimus gel
was also added without response. At that time his CD4 cell
count was 351 cells/mm3, and HIV-1 RNA 85 700 copies/mL.
Antiretroviral therapy with zidovudine, lamivudine, abaca-
vir, and lopinavir/ritonavir was then started. The oral lesions
improved successfully in one week of treatment and finally
completely re-epithelized in one month. His CD4 cell count
was then 383 cells/mm3, and HIV-1 RNA 46 600 copies/mL. He201-9712/$32.00 # 2006 International Society for Infectious Diseases.continued antiretroviral treatment for 10 further months
without recurrence of the oral ulcers. Currently his CD4 cell
count is 624 cells/mm3 and HIV-1 RNA is 85 700 copies/mL.
Recurrent aphthous ulcers are a common condition among
the general population. Although the majority of cases are
benign and spontaneously resolve in less than two weeks,
these ulcers may be indicative of an underlying systemic
disease such as vitamin deficiency or immune disturbance.
Recurrent aphthous ulcers (RAU) are usually classified as
minor, major, and herpetiform according to the ulcer size
and number.
The diagnosis of HIV-induced RAU requires a careful his-
tory of the condition. Oral mucosal biopsies are required for
non-healing ulcers in order to exclude the possibility of deep
fungal infections, viral infections, and neoplasms. The cause
of the ulcers in HIV-positive persons has not been elucidated;
local diseases, genetic, immunologic, and infectious factors
all probably play a role. Common or notable HIV-related oral
conditions include xerostomia, candidiasis, oral hairy leuko-
plakia, periodontal diseases such as linear gingival erythema
and necrotizing ulcerative periodontitis, Kaposi’s sarcoma,
human papilloma virus-associated warts, and ulcerative con-
ditions including herpes simplex virus lesions, recurrent
aphthous ulcers, and neutropenic ulcers.
In HIV-1-infected patients, oral ulcers commonly adopt
major forms and can be progressive and destructive. Dyspha-
gia and secondary malnutrition are frequently seen in
advanced cases. Additionally, ulcers usually fail to respond
to conventional therapy.1
Herpetic lesions in HIV-1-infected patients are not infre-
quent.2 They can show deeper andmore chronic forms than in
uninfected subjects. Although less common, in some cases
ulcers are caused by cytomegalovirus, which is usually diag-
nosed by demonstrating typical basophilic inclusion bodies on
biopsy samples, and confirmed by cultures. A co-infection of
viral ulcers may occur. Bacterial ulcers are less frequent, and
they are seen in a septic oral cavity presenting as a bad
smelling necrotic ulcer in which anaerobic infection plays an
important role.
Ulceronecrotic lesions in the sublingual area and tongue
can be seen in drug users who inject opioid sublingually.3
Mycotic ulcers are most frequent in HIV-1-infected patients
and are usually caused by Candida, but these ulcers are more
superficial and easily diagnosed by a direct exam with potas-
sium hydroxide stain. Syphilitic lesions may also present asPublished by Elsevier Ltd. All rights reserved.
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Figure 1 Ulcers localized in palate and labial mucosa before
HAART.painless indurative ulcers with lymphadenopathies, and thus
oral ulcer evaluation must include serologic tests for syphilis.
Non-infectious disorders causing oral ulcers in immuno-
suppressed patients include oral lichen planus, erosive Kaposi
sarcoma, and oral malignancies such as squamous cell carci-
noma or, less commonly, oral lymphoma.
In rare cases it is necessary to rule out rare associated
systemic disorders such as Behc¸et’s disease4 and complex
aphthosis variants, like ulcus vulvae acutum, mouth and
genital ulcers with inflamed cartilage (MAGIC syndrome),
fever, aphthosis, pharyngitis, and adenitis (FAPA syndrome),
and cyclic neutropenia. The association of lesions of RAUwith
hematologic disorders, vitamin deficiency, or gastrointestinal
diseases has also to be excluded and provides the opportunity
to identify a ‘correctable cause’.
Topical treatments, such as antimicrobial mouthwashes
and topical corticosteroids, can achieve pain relief and
reduction of ulcer duration but usually do not modify recur-
rence rates or remission time. In some cases, topical gran-
ulocyte-macrophage colony-stimulating factor has proven to
be efficacious in controlling HIV-related ulcers.5 When topical
treatment is unsatisfactory or patients suffer lesions con-
tinuously, systemic therapy may be considered, including
colchicine, levamisole and, in severe cases, oral corticoster-
oids or thalidomide.6 Thalidomide shows a significant ability
to eliminate painful mouth ulcers in HIV-1-infected patients.7
TNF-a production is increased in peripheral blood lympho-
cytes of patients with RAU. Thalidomide has the capacity for
inhibiting TNF-a production, and is an effective treatment
for RAU. However, it has some important side-effects that
include rash, peripheral neuropathy, and may increase HIV-1
RNA levels.8 In addition, thalidomide is effective during
treatment but not at lower intermittent doses in preventing
recurrence.9
The increased severity of RAU in HIV-1-infected patients
suggests that immunity changes related to this disease
may play a role in exacerbating the ulcers. These immune
system changes are mainly characterized by low CD4
cell counts. The rapid improvement in our patient whenantiretroviral treatment was initiated before immune
restoration could take place, suggests that high viral antigen
burden plays a crucial role in the pathogenesis of HIV-1-
related major oral ulcers.
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